Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quetiapine Augmentation of Venlafaxine in Treatment Resistant Depression
NCT00253266Phase 4Completed
- Sponsor
- Max Planck Institute of Psychiatry
- Start
- Apr 2008
- Primary completion
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of quetiapine in major depressive disorder (MDD) and bipolar disorder (BD), sponsored by Max Planck Institute of Psychiatry. Primary endpoint: Hamilton Depression Rating Scale at 8 weeks. Started Apr 2008; status: completed.
02
Drugs
quetiapine
03
Conditions
major depressive disorder (MDD)bipolar disorder (BD)
Beyond the preview
Go deeper on NCT00253266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00253266.